A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (ING113097).

Trial Profile

A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (ING113097).

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2011

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Aug 2011 Actual patient number is 16 and additional trial investigator identified as reported by ClinicalTrials.gov.
    • 02 Aug 2011 Actual patient number is 16 and additional trial investigator identified as reported by ClinicalTrials.gov.
    • 26 Jul 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top